11 – 20 of 24
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The Authors' Reply to the Letter “Plasma tumour and metabolism related biomarkers differentiate PAH from HFpEF-PH may improve long-term prognosis”
(
- Contribution to journal › Letter
-
Mark
Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Elevated plasma WIF-1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Andfåddhet potentiellt allvarligt – kräver strukturerad utredning
(
- Contribution to journal › Article
- 2021
-
Mark
Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2020
-
Mark
Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics
(
- Contribution to journal › Article
-
Mark
Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics
(
- Contribution to journal › Article